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Brittle cornea syndrome (BCS) is an autosomal recessive disorder characterised by extreme corneal thinning and
fragility. Corneal rupture can therefore occur either spontaneously or following minimal trauma in affected patients.
Two genes, ZNF469 and PRDM5, have now been identified, in which causative pathogenic mutations collectively
account for the condition in nearly all patients with BCS ascertained to date. Therefore, effective molecular
diagnosis is now available for affected patients, and those at risk of being heterozygous carriers for BCS. We have
previously identified mutations in ZNF469 in 14 families (in addition to 6 reported by others in the literature), and in
PRDM5 in 8 families (with 1 further family now published by others). Clinical features include extreme corneal
thinning with rupture, high myopia, blue sclerae, deafness of mixed aetiology with hypercompliant tympanic
membranes, and variable skeletal manifestations. Corneal rupture may be the presenting feature of BCS, and it is
possible that this may be incorrectly attributed to non-accidental injury. Mainstays of management include the
prevention of ocular rupture by provision of protective polycarbonate spectacles, careful monitoring of visual and
auditory function, and assessment for skeletal complications such as developmental dysplasia of the hip. Effective
management depends upon appropriate identification of affected individuals, which may be challenging given the
phenotypic overlap of BCS with other connective tissue disorders.
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Brittle cornea syndrome (BCS) is an autosomal recessive
condition that results from pathogenic variants in one of
two genes, ZNF469 [1,2] and PRDM5 [3,4]. BCS is a rare
condition, although the recent identification of mutations
in patients with thin corneas as part of a generalised
connective tissue disorder not previously clinically defined
as BCS [3] suggest that it may be under-diagnosed.
The recent identification of a patient with BCS with an
ocular-only phenotype [5] also supports this hypothesis, as
does the extremely high proportion of patients identified to
date who have consanguineous parentage. Whilst the very
high risk of ocular rupture is the most characteristic feature
of BCS, it is a multisystem connective tissue disorder, and a* Correspondence: graeme.black@manchester.ac.uk
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distribution, and reproduction in any mediumvariety of extra-ocular manifestations have been reported,
particularly deafness [3]. Due to only recent identification
of the causative genes for BCS, no previous article has
addressed the clinical presentation and management of
this condition in patients with a molecular diagnosis, or
been able to assess for genotype-phenotype correlation.
Here we summarise phenotypic data from affected patients,
and make recommendations for clinical management
(including molecular diagnosis) based on past experience
and currently available evidence.Methods
Patients whose data we included in this study were those
in whom mutations in PRDM5 and ZNF469 have been
identified in our laboratories as previously described
[3,6], and others published in the scientific literature whose
mutational status has been published. Clinical and molecu-
lar data were assessed for evidence of genotype-phenotype
correlations. Approval was granted by North Manchester
NHS Research Ethics Committee, reference 06/1406/52,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Results
Ophthalmic phenotypes
The striking ocular phenotype of BCS serves to distinguish
it from other similar conditions including many forms of
Ehlers-Danlos Syndrome (EDS). Clinical features are listed
in the Summary of common features in patients with BCS.
In its classical form, BCS is characterised by extreme
corneal fragility and thinning, often leading to corneal per-
foration either spontaneously or after minor trauma [1,7,8].
Corneal perforation is frequently observed as young as 2–3
years of age in BCS, emphasising the critical importance
of early identification of this condition. As a generalised
connective tissue disorder, involvement of multiple tissues
can usually be demonstrated, but the recent identification
of a single patient with BCS due to a homozygous frame
shift mutation in ZNF469 and no extra-ocular manifesta-
tions by the age of 37 years [5] is notable as it suggests that
such mutations could cause non-syndromic presentations
in other patients, and therefore, potentially be a rare cause
of keratoconus or apparently isolated corneal rupture.
Summary of common features in patients with BCS
OPHTHALMIC
Thin cornea, with or without rupture (central corneal
thickness often <400 μm)
Enucleation or corneal scarring as a result of previous
rupture
Progressive loss of corneal stromal depth, especially in
central cornea
Blue sclera
Early onset progressive keratoconus and/or
keratoglobus
High myopia, with normal or moderately increased
axial length
Retinal detachmentAUDITORY
Deafness, often with mixed conductive and
sensorineural components
Hypercompliant tympanic membranes
Progressive deafness, higher frequencies often more
severely affected (‘sloping’ pure tone audiogram)MUSCULOSKELETAL
Developmental dysplasia of the hip
Hypotonia in infancy, usually mild if present
Scoliosis
Arachnodactyly
Small joint hypermobility, pes planus, hallux valgus
Mild contractures of fingers (especially 5th)SKIN
Soft, doughy skin; other skin manifestations
(hyperelasticity, abnormal scarring) are usually mild if
present
Nearly all patients with BCS become blind from com-
plications of corneal perforation and resultant scarring
(Figure 1a). Other ocular features that affect vision are
keratoconus, keratoglobus and high myopia. These occur
because BCS corneas are unable to withstand normal
biomechanical stresses and hence cannot maintain their
structural integrity and shape. A high index of suspicion
may be required to make the diagnosis in milder cases in
which corneal thinning has not yet led to rupture [1,7,9].
Where it has been possible to fully assess corneal
thinning, the large majority of patients with BCS have
had central corneal thickness (CCT) of less than 400 μm
(normal range 515–575 μm [10]). On pachymetry, thinning
has been most pronounced in the central cornea, with
relative preservation of peripheral corneal thickness
(Figure 2a).
Blue sclerae are usually present in those affected by
BCS, but this is not universal [5], may disappear over
time, [11] is also present in many individuals identified
to be heterozygous carriers for BCS-associated mutations
[3,7], and may also occur in normal individuals. The pres-
ence of a blue sclera is believed to correlate with a reduc-
tion in scleral thickness of at least one third [8].
Further ophthalmic features have been reported in
BCS. Secondary glaucoma has been reported in many
affected patients, particularly those with extensive corneal
damage following rupture. One such patient, who was in
his fifth decade, whose eyes had axial lengths of 26.7 mm
and 22.5 mm (normal range: 21.5 – 23 mm) had also
suffered bilateral retinal detachments (patient IV:6 in
Christensen et al. [2]). Retinal detachments were also
noted in one other patient with BCS, a 5-year old boy
diagnosed clinically in the pre-molecular era [12]. Retinal
detachment does not appear to be a common ocular fea-
ture of BCS, but this observation is influenced by the early
age at which most patients have been examined or had to
undergo enucleation. Secondary glaucoma as a contributor
to blindness had not been previously highlighted in BCS,
but is now increasingly recognised [6].
Individuals heterozygous for BCS-associated mutations
have been reported to have a relevant phenotype, including
blue sclerae and small joint hypermobility [3]. These are
not always present, and in particular may not be striking
in adult carriers, but nonetheless can cause diagnostic
confusion, particularly in multiply consanguineous fam-
ilies where there may be potentially at-risk individuals
across several generations. Heterozygous carriers for BCS,
where formally assessed, have often been found to have
mild corneal thinning, for example CCT measurements
Figure 1 Clinical appearance of patient with BCS. This patient has a homozygous ZNF469 c.6444delG mutation (patient P3, Rohrbach et al. [6]) and is
pictured at 18 years of age: a) face, b) hands and c) feet. Note extensive corneal scarring bilaterally and blue sclerae. Her facial appearance is reminiscent
of several other patients with BCS, with a short nose, but otherwise unremarkable morphology. Several naevi are present over her cheeks and the lesions
on her forehead are small scabs. In the hands, bilateral clinodactyly is seen, and in the feet, pes planus and scars of previous surgical management of
hallux valgus.
Figure 2 Investigations in BCS. (a) Ocular optical coherence tomography (OCT) and pachymetry of a 32 year old patient with homozygous mutation
in PRDM5 (deletion of exons 11–16; IV:4 of family BCS-001, Burkitt Wright et al. [3]). Note extreme thinning, particularly of the central cornea (300 μm) but
even the maximum thickness at the periphery is only 330–380 μm. (b) Ocular OCT and pachymetry of a 31 year old patient with heterozygous mutation
in PRDM5 (IV:8, BCS-001). Note only mild corneal thinning on OCT, with mean CCT measurement of 480 μm, increasing to 580–620 μm at the periphery.
(c) Ocular OCT and pachymetry of a normal eye for comparison with a) and b), showing CCT of 580 μm and peripheral thickness of 650–750 μm.
(d) Tympanogram of BCS patient (IV:4, BCS-001): a Type Ad curve is observed, demonstrating normal middle ear pressure but hypercompliance of the
tympanic membrane. The volume by which the eardrum is displaced when a pulse of pressure is delivered to it is represented by the curve (~3.5 cm3),
whilst the marker on the left demonstrates the degree of compliance observed (~1 cm3) for a normal tympanic membrane.
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limitation to accurate clinical confirmation of disease
status. Keratoconus has also been diagnosed in a young
adult known to be heterozygous for a mutation in PRDM5
(IV:8, BCS-001, of Burkitt Wright et al. [3]).
Auditory phenotype
The audiological features of brittle cornea syndrome are
less frequently reported and of less dramatic onset than
many of the ophthalmic complications, and hence have
not yet been as comprehensively studied. The largest
previous survey of affected patients, collated in the pre-
molecular era [13] suggested that at least one third may
have significant problems with hearing, including severe
to profound deafness in some individuals. This is borne
out by the identification of variable degrees of deafness
in three of seven families with PRDM5-associated BCS,
including all affected individuals in families BCS-001 and
BCS-002 in which mutations were first identified [3]. The
degrees of deafness in these two families ranged from a
hearing loss of 25–30 dB mild enough to require no inter-
vention in a 30 year old woman (IV:6 of BCS-002), to se-
vere bilateral deafness in early childhood (IV:9 of BCS-001).
Deafness was also present in two of three unrelated com-
prehensively assessed patients with ZNF469 mutations [6].
Both inter- and intra-familial variability with respect to
age of onset and progression of deafness have been
observed, and a mixed aetiology with sensorineural
and conductive components has often been suggested, with
conductive components predominating in childhood. In
keeping with this, some patients have derived benefit from
tympanostomy in childhood, but others have not had
evidence of glue ear, and hypermobility of the ossicular
chain has been implicated [3].
Where tympanometry has been performed, hyper-
compliant tympanic membranes, as may be seen also in
association with other generalised connective tissue
disorders, have been demonstrated in a very high proportion
of patients (Figure 2d). Hypercompliant tympanic mem-
branes are thought to be caused by a combination of factors,
including increased intrinsic compliance of the eardrum
itself, and joint laxity between the ossicles of the middle
ear [14]. Tympanometry is a non-invasive test routinely
available in audiological medicine and may therefore be
a useful diagnostic procedure to assess the likelihood
of BCS. The identification of hypercompliant tympanic
membranes should prompt further consideration of BCS
as a possible diagnosis. No evidence of hearing loss or
abnormal tympanometry in heterozygous individuals
has yet been identified.
Other features
In keeping with a generalised connective tissue disorder,
musculoskeletal features have been present in manypatients with BCS, most notably developmental dysplasia
of the hip (DDH) and scoliosis. DDH or other hip
abnormalities in childhood have been present in several
affected individuals, for example all four affected siblings
of BCS-001 and two of four affected individuals of
BCS-002 [3]. Scoliosis also affects a significant proportion
of patients, such as those of Christensen et al. [2]. Reduced
bone mineral density has been observed in adults with
BCS due to PRDM5 [3] or ZNF469 mutations [2], even
amongst those with normal Vitamin D status. Repeated
fractures have also been reported in a significant minority
of affected patients.
Small joint hypermobility has been notable in the
majority of affected individuals and present to a milder
degree in many of their relatives without BCS (especially
those who were heterozygous carriers for the causative
mutation). Mild contractures of the 5th fingers have been
noted in several patients (Figure 1b), but have not usually
required active treatment in this young patient cohort.
Hallux valgus (Figure 1c), a common finding in the general
population, has again been noted in several people with
BCS, including with an unusually early age of onset.
The patient in Figure 1, P3 in Rohrbach et al’s series,
[6] required surgery aged 14 years to manage severe
deformity. Easy bruising has been noted in many affected
individuals, but skin healing and scarring have usually
appeared to be normal or only mildly altered.
Obstetric and perinatal problems reminiscent of those
seen in other connective tissue disorders have also been
present in several individuals with BCS: premature birth
after premature rupture of membranes (V: 1, BCS-002),
and primary primiparous cervical incompetence, resulting
in second trimester pregnancy loss (IV:4, BCS-001)
have each been observed in individuals with mutations
in PRDM5 [3].
Mitral valve dysfunction and cardiovascular symp-
tomatology has also been identified in more than one
individual with BCS, and echocardiography may therefore
be warranted in this patient group. Importantly, vascular
ruptures as have occurred in EDS VI (Kyphoscoliotic type)
[15] have not been reported in BCS patients to date.Discussion
Differential diagnosis
Differential diagnoses of BCS are summarised in Table 1.
These have long been known to include Ehlers-Danlos
syndrome (EDS) type VI (OMIM: 225400), formerly
described as EDS VIA. Indeed, BCS has previously, on
occasion, been termed EDS VIB, however, this nomencla-
ture has also been used for a range of other phenotypes
that, like BCS, show a normal LP:HP ratio, but are genetic-
ally and, usually, clinically, distinct from it, such as the
musculocontractural form of EDS (OMIM: 601776). This
Table 1 Differential diagnosis of BCS: autosomal recessive connective tissue disorders with blue sclera and thin cornea
Condition / phenotype OMIM Gene Protein OMIM
BCS 229200 ZNF469 Zinc finger protein 469 612078
614170 PRDM5 PR domain containing 5 614161
EDS VI 225400 PLOD1 Lysyl hydroxylase 1 153454
EDS, musculocontractural type 601776 CHST14 Carbohydrate sulfotransferase 14 608429
EDS with progressive kyphoscoliosis, myopathy and hearing loss 614557 FKBP14 FK506 binding protein 14 614505
Bone fragility with contractures, arterial rupture and deafness 612394 PLOD3 Lysyl hydroxylase 3 603066
Spondylocheiro dysplastic type of EDS 612350 SLC39A13 ZIP3 608735
Other, rare, autosomal recessive forms of Ehlers Danlos syndrome (EDS) and osteogenesis imperfecta (OI) have also been characterised, but these would be
unlikely to present within the differential diagnosis of BCS, for example the dermatosparactic form of EDS (VIIc, OMIM 604539, due to mutations in ADAMTS2 [39])
has dramatic skin manifestations not seen to date in BCS patients, whilst the extremely rare patients with recessive OI due to biallelic mutations in collagen I or V
genes have usually had severe bone fragility and again no dramatic eye phenotype reported. Recessive CRTAP mutations also appear to result in severe bone
phenotypes but without significant ophthalmic complications [40], making it likely that these severe recessive OI presentations would be able to be differentiated
from BCS.
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separate entity.
Clinical differentiation between EDS VI and BCS may
be challenging, but patients with EDS VI frequently have
more pronounced generalised connective tissue manifesta-
tions. Premature death from arterial or visceral rupture,
similar to that seen in EDS type IV (OMIM:130050) is well
documented in EDS type VI [15,16], but no such complica-
tions have yet been described in BCS. The small numbers
of patients identified to date, however, and their pre-
dominantly young ages, mean that modestly increased
risks for such sequelae cannot currently be excluded.
In keeping with more marked generalised connective
tissue effects, a greater degree of muscular hypotonia
in infancy may be seen in EDS VI [15] than has been
recorded in BCS. Similarly, scoliosis may be seen in ei-
ther condition, but severe early onset scoliosis may be
more characteristic of EDS VI [15]. An algorithm to assist
diagnosis of BCS is suggested in Figure 3.
Other differential diagnoses for BCS include the
musculocontractural form of EDS, another autosomal
recessive connective tissue disorder (OMIM: 601776),
due to biallelic mutations in CHST14 [17]. Indeed, one
individual whose sample was referred for genetic testing for
BCS following corneal rupture was subsequently found to
have a homozygous mutation in CHST14. Fixed adducted
thumbs have been described as a characteristic clinical fea-
ture of patients with CHST14 mutations, in contrast to the
5th finger contractures that result in the mild camptodactyly
noted in several patients with BCS (Figure 1b).
Further recently described variant forms of EDS,
such as that with progressive scoliosis and deafness
(OMIM: 614557) due to biallelic mutations in FKBP14,
may also show clinical overlap with BCS [18], though the
full range of clinical phenotypes due to mutations in these
and other newly identified genes requires further definition.Features that differentiate BCS from EDS type VI are
the presence of obvious and dramatic ocular signs in
children with BCS, alongside mild or absent features of
generalised connective tissue disorder. Overall, ocular
sequelae across the different forms of EDS are rare: an
early review of 100 individuals with EDS phenotypes did
not reveal any serious ophthalmological complications
[19]. In a series of 8 cases reported as EDS with ocular
manifestations [11], those with serious ocular features
were likely to actually have BCS, as demonstrated by the
identification of PRDM5 mutations in two patients of
this series [3]. These individuals had corneal fragility and
ruptures, blue sclera, keratoconus in early childhood, and
also had consanguineous parents, increasing the likelihood
of an autosomal recessive disorder [11]. Scleral fragility has
been considered a feature of EDS type VI, whereas corneal
fragility is a key feature of BCS. Systematic data on CCT
measurements in patients with EDS VI are currently
lacking, but CCT around or below 400 μm would appear
to a potentially robust diagnostic indicator of BCS.
Muscular hypotonia can be pronounced in EDS type
VI, leading to significantly delayed motor development.
Such severe delay has not been observed in BCS, with
either normal or mildly delayed motor milestones being
observed. Vascular abnormalities also appear more
prevalent in EDS type VI than in BCS.
Other disorders characterised by blue sclera and potential
corneal fragility that may occasionally enter the differential
diagnosis of BCS include the spondylocheirodysplastic form
of EDS (SCD-EDS) (OMIM: 612350) [20,21], osteogenesis
imperfecta (OI; OMIM: 166200) and Marfan syndrome
(OMIM: 154700) [13]. Blue sclerae were a feature of SCD-
EDS in the 3 families reported to date with this condition.
However, one of the two probands from another mo-
lecularly confirmed affected family developed unilateral
lattice corneal dystrophy with keratoconus in her
Figure 3 Diagnostic algorithm for patients with suspected
brittle cornea syndrome.
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syndrome and most forms of OI show autosomal dominant
inheritance, but with a significant proportion of new
mutations, so family history may be uninformative, but
clinical distinction between these disorders and BCS
should nonetheless normally be possible. Both OI and
Marfan syndrome have cardinal clinical features which
are not characteristically seen in BCS: in OI, a history
of recurrent and sometimes spontaneous fractures, and
in Marfan syndrome, tendency to aortic dissection, tall
stature and ectopia lentis (lens subluxation).Figure 4 Mutational spectrum in patients diagnosed with BCS. Note a g
wide spectrum of mutations consistent with loss-of-function alleles. ArticlesGene function, mutational spectrum and correlation with
phenotype
As can be seen from Figure 4, there is a wide mutational
spectrum observed across the two genes known to be
responsible for BCS. Both genes encode proteins with
multiple zinc fingers, suggesting roles in transcription,
and PRDM5 has been identified as a sequence-specific
transcription factor [22].
ZNF469 is a 13 kb open reading frame at 16q24
consisting of a single exon [6] predicting production of a
413 kDa protein of 3953 amino acid residues. Whilst
functional data for ZNF469 is limited, its locus has been
repeatedly identified as a top hit in genome-wide associ-
ation studies for central corneal thickness, confirming its
importance in anterior segment development, [25,26] with
concomitant implications for pathogenesis of common
ocular disorders such as glaucoma [27].
PRDM5 is a 16 exon gene at 4q25-q26 encoding a
73 kDa protein of 630 amino acid residues. Its role in
extracellular matrix (ECM) development has recently
been investigated in vivo [28]. PRDM5 was identified to
bind to the exonic DNA of collagen I genes and to up-
stream enhancer elements of proteoglycans with key
roles in the ECM, such as decorin, in murine bone [28].
Mutations identified to date in patients with BCS are
shown in Figure 4. The high proportion of frameshift
and premature truncation mutations across both genes
is in itself highly suggestive that these act as loss-of-
function alleles. Their functional effects upon componentsreater proportion of mutations in (a) ZNF469 than (b) PRDM5, and a
in which the mutations are described are listed below [23,24].
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derived fibroblasts [3,6]. Total numbers of known affected
patients are quite small, but notwithstanding this, there is
no current evidence of genotype-phenotype correlation:
mutations in either gene appear to cause indistinguishable
clinical phenotypes, as shown in Table 2. There is currently
no indication that milder or more severe presentations
might result from missense substitutions, or other genres
of mutation. Similarly, functional assessment of mutated
PRDM5 and ZNF469 proteins in skin-derived fibroblasts
[3] showed very similar results for each at the RNA
level by expression microarray and at the protein level
by immunofluorescence. Specific molecular or cellular
signatures for phenotypic features, such as high risk of
corneal rupture (as in family BCS-001) versus no corneal
rupture (family BCS-002), or multiple fractures (BCS-002)
versus no fractures (BCS-002), have also not yet been iden-
tified [3]. Further evidence regarding the full phenotypic
spectrum and genotype-phenotype correlation will emerge
as increasing numbers of patients receive a molecular
diagnosis, and known patients can be reviewed at more
advanced ages. The data available for many patients in the
literature is limited, and later onset phenotypes such as
scoliosis are likely to be under-represented. Similarly, the
presence or absence of later onset features such as retinal
detachment or glaucoma in severely compromised eyes
may or may not have been recorded for some patients,
again leading to underestimates of the incidence of such
sequelae in BCS.Clinical management
There are many facets to the management of BCS,
which are summarised and discussed below. Given the
high risk of poor visual outcomes following corneal rup-
ture, recognition of this disorder prior to the occurrence
of rupture is a critical step in preserving function and
quality of life for affected patients.Table 2 Common clinical features of BCS in patients with bial
Feature Observed in how many
(and families) with ZNF
Ocular rupture 16/19 (8 of 11 families)
CCT <400 μm 12/12 (7 families)
Keratoconus/keratoglobus* 8/12 (7 families)
Blue sclera 19/19 (11 families)
Deafness 7/17 (6 of 11 families)
Developmental dysplasia of the hip 5/14 (4 of 10 families)
Scoliosis 3/18 (2 of 7 families)
Small joint hypermobility 12/19 (8 of 11 families)
Other features reported in small numbers of affected individuals or families include
orofacial clefting. Such features could represent less common features of BCS or co
consanguineous pedigrees).
* Whilst keratoconus or keratoglobus have not been noted in all affected individuaManagement checklist for patients with brittle cor-
nea syndrome.
OPHTHALMIC: ensure ongoing ophthalmology
follow-up
Education and lifestyle advice: patient, family, school
and other carers
Protectivepolycarbonate spectacles (activities for which
mandated may depend upon history and degree of
corneal thinning)
Serial corneal scanning
AUDIOLOGICAL: ensure ongoing audiological
follow-up
Serial pure tone audiometry and tympanography
MUSCULOSKELETAL
Newborns and children under 2 years: screening for
hip dysplasia
Be alert to other connective tissue phenotypes: monitor
for scoliosis
Joint protection advice
OTHER CLINICAL MANAGEMENT
Consider echocardiography, low threshold for cardiac
investigation
Be aware of potential pregnancy-related complications
FAMILY IMPLICATIONS
Molecular testing for confirmation of diagnosis
Assessment and genetic testing of other at-risk
individuals in family
Consider above interventions for heterozygous
mutation carriers
Early diagnosis is crucial
Definitive clinical diagnosis of BCS can be difficult, and
hence genetic testing for BCS is relevant for affected,lelic ZNF469 and PRDM5 mutations
patients
469 mutations?
Observed in how many patients
(and families) with PRDM5 mutations?
9/16 (5 of 8 families)
9/9 (4 families)
16/16 (8 families)
9/16 (3 of 8 families)
4/16 (3 of 8 families)
3/16 (3 of 8 families)
14/16 (7 of 8 families)
recurrent fractures, dental abnormalities, learning disability, hypertelorism and
incidental phenotypes (particularly in individuals from multiply
ls, this most frequently appears to be due to extremely early corneal rupture.
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carriers of heterozygous mutations. The condition may
be more likely to remain undiagnosed in patients without
factors suggestive of autosomal recessive inheritance, for
example simplex cases who are children of unrelated
parents. It is also possible that penetrating corneal
injuries due to BCS, particularly those without a clear
history of significant trauma, could be misattributed to
non-accidental injury (NAI). Clearly the possibility of
NAI must be considered in any such case, but we are
aware of allegations of NAI in at least two families affected
with BCS (personal communications), in which a child
presented initially with corneal rupture. Awareness of the
disorder and careful clinical evaluation are required to
differentiate NAI from BCS.
Prevention of ocular rupture
The key challenge in the management of BCS is the pre-
vention of ocular rupture, which relies on early diagnosis
to allow for targeted measures aimed at preventing
ocular trauma. A multidisciplinary approach is needed,
with provision of both protective polycarbonate spectacles
and appropriate education about these and other lifestyle
measures for affected individuals, their parents, other
caregivers and school staff. As early as 1990, early diagnosis
(aged 2 years) of BCS was reported in a patient in whom
corneal perforation was averted by the use of special
protective glasses [29]. For BCS patients who have very
thin corneas, or who have an affected relative who has
suffered a corneal rupture, continuous wearing of such
eyewear should be recommended, given the multiple
identified instances of perforating ocular trauma following
the most minor of impacts. For patients with any degree of
reduced central corneal thickness, the wearing of protective
eyewear should be recommended for active pursuits,
but whether continuous use is necessary for these patients
is less clear.
Optimising visual function
Visual acuity is affected from an early age by keratoconus,
keratoglobus and high myopia. Correction of the irregular
astigmatism caused by keratoconus and keratoglobus is of
limited efficacy. In addition, the use of contact lenses is
frequently precluded by extreme corneal thinning [30].
Maximising visual potential in BCS is particularly import-
ant given the high proportion of patients with combined
visual and hearing loss.
Clinical surveillance of BCS patients for progression of
the ocular phenotype is warranted. Progressive corneal
ectasia may occur prior to ocular rupture [11] and serial
corneal topography can detect progressive thinning.
Any evidence of progression would be a strong indication
for the provision of protective spectacles, if not already in
use. In at least one patient with BCS, a scleral contact lensworn beneath protective spectacles has been considered
for refractive correction of keratoconus (personal commu-
nication), though the risk-benefit analysis for any such
intervention would be different for each individual. In
advanced cases of corneal thinning, epikeratoplasty has
been advocated in anticipation of corneal rupture. This
is a partial thickness corneal graft that aims to increase
limbus-to-limbus thickness and permit a full thickness
corneal transplant to be performed over it subse-
quently [30]. This technique is aimed to accommodate
the fragility of the recipient bed and disparity between
donor and recipient tissue thickness [30,31], preserving
globe integrity and improving vision. Javadi et al. [30]
performed epikeratoplasty in 7 eyes of 6 patients with ad-
vanced keratoglobus or BCS, with mean preoperative cor-
neal thickness of 277 μm. Visual improvements were
noted, but so too were significant complications. A
neurotrophic ulcer developed in one patient, and epi-
thelial down-growth into the corneal stroma in another
patient. Penetrating keratoplasty a few months after
epikeratoplasty was therefore advocated for cases of
extreme corneal thinning [30,32]. Additional surgical
options for extreme corneal thinning include corneo-
scleral grafting, which will not improve vision, but may
strengthen the peripheral cornea [33].
Collagen crosslinking has been reported to be effective
in treating progressive keratoconus in children and
adults [34,35]. This technique involves application of
riboflavin (vitamin B2) and long wavelength ultraviolet A
light (370 nm) to induce chemical reactions in the corneal
stroma, resulting in the formation of covalent bonds
between the collagen molecules, fibres and microfi-
brils, strengthening the cornea [36]. Modified collagen
crosslinking was recently performed for corneal sta-
bilisation in a child with BCS seen in our clinic, with
encouraging preliminary results. Vision improved from
0.05 to 0.16p in one week, and no complications were
apparent one month after the procedure. A child with se-
vere corneal manifestations of arterial tortuosity syndrome
(ATS) has also been successfully treated in a similar
manner: one year after the procedure, reduced corneal
curvature and a sustained improvement in visual acuity
were observed. CCT in both children was 270 μm.
Treatment of corneal rupture
The management of corneal rupture in BCS is challenging.
When primary repair has been attempted, this has often
been complicated by extensive scarring. When primary
repair is not possible, or fails, affected individuals usually
require an evisceration. Corneal transplantation to treat
extensive scarring after previous rupture has been reported
in BCS, but specific complications and considerations have
been identified [12]. The efficacy of corneal transplantation
in the setting of a diffusely thinned recipient bed is limited.
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a child with BCS and spontaneous corneal rupture. They
used a traditional limbus-to-limbus technique but placed
sutures further across the recipient cornea in order to
prevent “cheese-wiring” through the tissue. Despite this
precaution, an intraoperative corneal rupture occurred,
when rotation of the sutures to bury the knot from the
corneal surface was attempted [12]. A scleral allograft
was used to seal the rupture and the child was able to
be discharged with a secure wound and visual acuity of
20/100 two weeks postoperatively [12]. However, such
limbus-to-limbus corneal grafts are associated with an
increased risk of rejection [30]. Macsai et al. [37] described
successful emergency epikeratoplasty in a patient with a
ruptured cornea and diagnosis of “ocular Ehlers-Danlos
syndrome” with normal lysyl hydroxylase levels. No genetic
testing has been reported in this patient, but the clinical
and biochemical presentation was strongly suggestive
of BCS. This was reported as the first successful such
procedure, citing the report of Judisch et al. [38] as the
first attempt, which ended in enucleation. Similarly, in
an early case series of 5 patients with keratoglobus and
blue sclera, 2 patients underwent penetrating kerato-
plasty that was unsuccessful, necessitating subsequent
evisceration [31].
Management of extraocular manifestations
BCS is a multisystem connective tissue disorder in the
great majority of cases, but extraocular manifestations
are commonly milder than those seen in many other
connective tissue disorders. Data are not available for
older patients affected with BCS, but there is currently
no evidence for a reduction in life expectancy, in con-
trast to the high early mortality observed in EDS VI [15]
and in many other autosomal recessive connective tissue
disorders.
Significant musculoskeletal complications have none-
theless been seen in a high proportion of patients with
BCS, particularly developmental dysplasia of the hip
(DDH), which has been of unusually late onset in at least
one individual (V:4, BCS-002, Burkitt Wright et al.), when
it presented in the second year of life following normal
neonatal and 6 week checks. This suggests that a high
index of suspicion is required in these patients, and
that the duration of surveillance for hip dysplasia
should perhaps be extended beyond that routinely offered
for at-risk infants. Scoliosis is also a common feature of
BCS, and therefore affected individuals should be clinically
monitored for this, with a low threshold for proceeding to
investigations. At present, there are no data to suggest
differences in how these and the other musculoskeletal
features of BCS should be managed as compared to
such complications in the context of other generalised
connective tissue disorders.Heterozygous mutation (carrier status) in one of the
genes mutated in BCS may be associated with mild ocular
and musculoskeletal manifestations. Both keratoconus and
high myopia have been identified in known heterozygous
carriers and comprehensive ocular examination is indicated
in individuals with (or at risk for) such mutations.
Whilst there is currently little evidence on the effects of
being a heterozygous mutation carrier, these genotypes may
also confer an additional risk of significant musculoskeletal
manifestations. Any potential increased risk of DDH
warrants particular attention, and a screening schedule
similar to that recommended for babies with a family
history of DDH may be appropriate. Whilst specific evi-
dence to support this is currently not available, significant
hypermobility has been observed in several heterozygous
individuals, suggesting that their individual risks of
developing DDH may indeed be elevated compared to
the general population.
Conclusions
We consider it likely that BCS remains an under-
recognised condition. In support of this assertion, only
one patient with BCS due to compound heterozygous
mutations has been identified to date (Patient P2 of
Rohrbach et al. [6]). BCS is a condition that is important
to recognise, in order to permit appropriate management,
including avoidance of misattribution of corneal damage to
non-accidental injury, and to facilitate genetic counselling.
With the identification of two genes underlying BCS,
molecular testing is now available and effective, with a
mutation demonstrable in over 95% of cases with a
classical presentation. Definitive diagnosis allows for
appropriate anticipatory management, including advice
and aids to prevent future ocular rupture and careful
assessment for combined sensory loss, with its major
implications for quality of life.
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